MX9606082A - Compuestos heterociclicos que tienen actividad antagonista de receptor de taquiquinina, su preparacion y su uso. - Google Patents

Compuestos heterociclicos que tienen actividad antagonista de receptor de taquiquinina, su preparacion y su uso.

Info

Publication number
MX9606082A
MX9606082A MX9606082A MX9606082A MX9606082A MX 9606082 A MX9606082 A MX 9606082A MX 9606082 A MX9606082 A MX 9606082A MX 9606082 A MX9606082 A MX 9606082A MX 9606082 A MX9606082 A MX 9606082A
Authority
MX
Mexico
Prior art keywords
substitutable
aryl
heteroaryl
alkylsulfoxide
alkenylene
Prior art date
Application number
MX9606082A
Other languages
English (en)
Inventor
Takahide Nishi
Koki Ishibashi
Katsuyoshi Nakajima
Tetsuya Fukazawa
Hitoshi Kurata
Takeshi Yamaguchi
Kazuhiro Ito
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of MX9606082A publication Critical patent/MX9606082A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describen compuesto de la formula (I) (Ver Formula) y sus derivados cuaternarios de amonio, especialmente compuestos en donde L representa un grupo (Ver Formula) que tienen actividad antagonista de receptor de taquiquinina y exhiben una actividad contra receptores NK1 como receptores NKz.
MX9606082A 1995-12-01 1996-12-02 Compuestos heterociclicos que tienen actividad antagonista de receptor de taquiquinina, su preparacion y su uso. MX9606082A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP31382895 1995-12-01
JP33636995 1995-12-25
JP29686996 1996-11-08

Publications (1)

Publication Number Publication Date
MX9606082A true MX9606082A (es) 1998-08-30

Family

ID=27338095

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9606082A MX9606082A (es) 1995-12-01 1996-12-02 Compuestos heterociclicos que tienen actividad antagonista de receptor de taquiquinina, su preparacion y su uso.

Country Status (19)

Country Link
US (2) US6159967A (es)
EP (1) EP0776893B1 (es)
CN (1) CN1142932C (es)
AT (1) ATE213738T1 (es)
AU (1) AU719158B2 (es)
CA (1) CA2191815C (es)
CZ (1) CZ288498B6 (es)
DE (1) DE69619479T2 (es)
DK (1) DK0776893T3 (es)
ES (1) ES2170211T3 (es)
HK (1) HK1011366A1 (es)
HU (1) HU224225B1 (es)
IL (1) IL119729A (es)
MX (1) MX9606082A (es)
NO (1) NO308300B1 (es)
NZ (1) NZ299859A (es)
PT (1) PT776893E (es)
RU (1) RU2135494C1 (es)
TW (1) TW367327B (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2135494C1 (ru) * 1995-12-01 1999-08-27 Санкио Компани Лимитед Гетероциклические соединения и композиция на их основе, проявляющая антагонистическое действие в отношении рецепторов тахикинина
PT987269E (pt) 1997-05-30 2003-11-28 Sankyo Co Sais de derivados sulfoxido opticamente activo
BR9815348A (pt) 1997-12-04 2000-10-17 Sankyo Co " composto, uso deste ou de um sal farmacologicamente aceitável, éster ou outro derivado do mesmo, medicamento, agentes preventivos ou terapêuticos para asma e/ou bronquite, para rinite, para doença alérgica, e para incontinência urinária, e, processos de prevenção ou tratamento de asma e/ou bronquite, de rinite, de doença alérgica, e de incontinência urinária. "
TR200002072T2 (tr) * 1998-01-23 2000-12-21 Sankyo Company Limited Spiropiperidin türevleri
WO2000034274A1 (fr) * 1998-12-10 2000-06-15 Sankyo Company, Limited Derives de la cyclohexylpiperidine
FR2791346B3 (fr) * 1999-03-25 2001-04-27 Sanofi Sa Nouveaux derives de morpholine, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2796069B3 (fr) * 1999-07-09 2001-08-24 Sanofi Synthelabo Nouveaux procedes de preparation de derives de 2-(2- arylmorpholin-2-yl)ethanol substitues, enantiomeriquement purs, et composes intermediaires utiles dans ces procedes
AU7952800A (en) * 1999-10-22 2001-04-30 Sankyo Company Limited 2-alkoxybenzene derivatives
ES2304984T3 (es) 1999-11-03 2008-11-01 Amr Technology, Inc. Tetra-hidroisoquinolinas de sustitucion arilica y heteroarilica y su utilizacion para bloquear la recaptacion de norepinefrina, dopamina y serotonina.
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
EP1299393A2 (en) 2000-07-11 2003-04-09 Bristol-Myers Squibb Pharma Company 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
FR2824828B1 (fr) * 2001-05-21 2005-05-20 Sanofi Synthelabo Nouveaux derives de piperidinecarboxamide, un procede pour leur preparation et les compositions pharmaceutiques les contenant
JP2004067673A (ja) * 2002-06-11 2004-03-04 Sankyo Co Ltd 環状チオエーテル類の製造法及びその合成中間体
US7396930B2 (en) * 2002-06-11 2008-07-08 Sankyo Company, Limited Process for producing cyclic thioether and synthetic intermediate thereof
AU2003242092A1 (en) * 2002-06-11 2003-12-22 Sankyo Company, Limited Process for producing cyclic thioether and synthetic intermediate thereof
MY141736A (en) * 2002-10-08 2010-06-15 Elanco Animal Health Ireland Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists
CN1729196A (zh) * 2002-10-24 2006-02-01 三共株式会社 旋光亚砜的制备方法
US7560549B2 (en) * 2004-02-25 2009-07-14 Sankyo Company, Limited Sulfonyloxy derivatives
CA2557539A1 (en) 2004-02-25 2005-09-01 Sankyo Company Limited Indanol derivative
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
FR2873373B1 (fr) * 2004-07-23 2006-09-08 Sanofi Synthelabo Derives de 4-arylmorpholin-3-one, leur preparation et leur application en therapeutique
NZ553202A (en) * 2004-08-19 2010-12-24 Vertex Pharma Modulators of muscarinic receptors
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
KR101589551B1 (ko) 2005-07-15 2016-02-02 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
EP1909788A2 (en) 2005-07-29 2008-04-16 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
PL2109608T3 (pl) 2007-01-10 2011-08-31 Msd Italia Srl Indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy)-(PARP)
JP2010516815A (ja) * 2007-01-31 2010-05-20 ヘラー， アダム 疼痛の治療のための方法および組成物
DK2118074T3 (en) 2007-02-01 2014-03-10 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
RU2520098C2 (ru) 2008-06-26 2014-06-20 Ресверлоджикс Корп. Способы получения производных хиназолинона
JP5635535B2 (ja) 2009-01-08 2014-12-03 レスバーロジックス コーポレイション 心血管疾患の予防および治療のための化合物
CA2992231C (en) 2009-03-18 2022-03-29 Resverlogix Corp. Phenyl-quinazolin-4(3h)-one and phenyl-pyrido[2,3-d]pyrimidin-4(3h)-one derivatives and compositions thereof useful as anti-inflammatory agents
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
KR20190091564A (ko) 2009-04-22 2019-08-06 리스버로직스 코퍼레이션 신규한 소염제
KR20120034644A (ko) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
AU2010247735B2 (en) 2009-05-12 2015-07-16 Albany Molecular Research, Inc. Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
US8802696B2 (en) 2009-05-12 2014-08-12 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
SI2606134T1 (sl) 2010-08-17 2019-08-30 Sirna Therapeutics, Inc. RNA-INTERFERENČNO POSREDOVANO ZAVIRANJE IZRAŽANJA GENA VIRUSA HEPATITISA B (HBV) Z UPORABO KRATKE INTERFERENČNE NUKLEINSKE KISLINE (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
IN2013MN02170A (es) 2011-04-21 2015-06-12 Piramal Entpr Ltd
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
CN103945848B (zh) 2011-11-01 2016-09-07 雷斯韦洛吉克斯公司 被取代的喹唑啉酮的口服即释制剂
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
BR102012024778A2 (pt) * 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
PL2925888T3 (pl) 2012-11-28 2018-03-30 Merck Sharp & Dohme Corp. Kompozycje i sposoby do stosowania w leczeniu nowotworów
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
CA2895905A1 (en) 2012-12-21 2014-06-26 Zenith Epigenetics Corp. Novel heterocyclic compounds as bromodomain inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
KR102662814B1 (ko) 2015-03-13 2024-05-03 리스버로직스 코퍼레이션 보체 관련 질환을 치료하기 위한 조성물 및 치료 방법
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3881843A4 (en) * 2018-11-15 2022-08-03 Kyushu University, National University Corporation PROPHYLACTIC OR THERAPEUTIC AGENT AND MEDICAL COMPOSITION FOR IL-31 MEDIATED DISEASE

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE903957A1 (en) * 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical preparations containing them
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2676054B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
GB9125515D0 (en) * 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
AU662943B2 (en) 1991-12-18 1995-09-21 Biosearch Italia S.P.A. 7'-amino-naphthazarin antibiotic derivatives
ES2119174T3 (es) 1993-01-28 1998-10-01 Merck & Co Inc Azaciclos espiro-sustituidos como antagonistas de los receptores de las taquiquininas.
CN1081635C (zh) 1993-05-06 2002-03-27 默里尔药物公司 取代的吡咯烷 －3－基－烷基－哌啶
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
WO1994029309A1 (en) * 1993-06-07 1994-12-22 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin antagonists
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
AU2223495A (en) 1994-04-15 1995-11-10 Yamanouchi Pharmaceutical Co., Ltd. Spiro compound and medicinal composition thereof
FR2729954B1 (fr) * 1995-01-30 1997-08-01 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2729951B1 (fr) * 1995-01-30 1997-04-18 Sanofi Sa Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2729952B1 (fr) * 1995-01-30 1997-04-18 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
RU2135494C1 (ru) * 1995-12-01 1999-08-27 Санкио Компани Лимитед Гетероциклические соединения и композиция на их основе, проявляющая антагонистическое действие в отношении рецепторов тахикинина
JP3192631B2 (ja) * 1997-05-28 2001-07-30 三共株式会社 飽和複素環化合物からなる医薬

Also Published As

Publication number Publication date
NO965125D0 (no) 1996-12-02
DE69619479D1 (de) 2002-04-04
EP0776893B1 (en) 2002-02-27
CA2191815C (en) 2005-05-10
US6448247B1 (en) 2002-09-10
IL119729A0 (en) 1997-03-18
NZ299859A (en) 1997-11-24
NO308300B1 (no) 2000-08-28
HUP9603298A2 (hu) 1998-09-28
DE69619479T2 (de) 2002-10-17
AU7406596A (en) 1997-06-05
HU224225B1 (hu) 2005-06-28
HU9603298D0 (en) 1997-01-28
NO965125L (no) 1997-06-02
RU2135494C1 (ru) 1999-08-27
CA2191815A1 (en) 1997-06-02
TW367327B (en) 1999-08-21
CZ352196A3 (en) 1997-06-11
DK0776893T3 (da) 2002-03-18
AU719158B2 (en) 2000-05-04
CN1142932C (zh) 2004-03-24
HK1011366A1 (en) 1999-07-09
IL119729A (en) 2001-07-24
EP0776893A1 (en) 1997-06-04
ES2170211T3 (es) 2002-08-01
HUP9603298A3 (en) 1999-10-28
US6159967A (en) 2000-12-12
ATE213738T1 (de) 2002-03-15
CN1157286A (zh) 1997-08-20
CZ288498B6 (en) 2001-06-13
PT776893E (pt) 2002-06-28

Similar Documents

Publication Publication Date Title
MX9606082A (es) Compuestos heterociclicos que tienen actividad antagonista de receptor de taquiquinina, su preparacion y su uso.
NZ331319A (en) Cyclic amine derivatives that are CCR-3 receptor (chemokine receptor) antagonists, compositions containing them and methods for their use (to combat eosinophil induced diseases).
IL101785A0 (en) Urea derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
BG103415A (en) Heteroaryl succinamides and their application as inhibitors of metalloproteinase
CA2264721A1 (en) A1 adenosine receptor antagonists
NZ334251A (en) 1,3-diheterocyclic metalloprotease inhibitors
TR200102957T2 (tr) Sitalopram hazırlanması için metod.
IL108562A (en) 7, 8-diaryl-1,2,3,4- terahydropyrazolo- £5,1-c| £1,2,4| triazine derivatives, methods for the preparation thereof and pharmaceutical compositions containing them
DE69420564D1 (de) Immunsuppressive und antiallergische verbindungen; z.b. n-(3-oxohexanoyl)-homoserinlacton
NZ335157A (en) N-(aryl/heteroaryl) amino acid derivatives and methods for inhibiting beta-amyloid peptide release or its synthesis
HK1019878A1 (en) Total synthesis of antitumor acylfulvenes.
TW342385B (en) Bicyclic benzazepin, the process for their preparation and the pharmaceutical composition containing them
RO86511B (ro) Procedeu pentru prepararea unor beta-lactame
DK0958280T3 (da) Arylpiperidinopropanol- og arylpiperazinopropanolderivater og farmaceutiske midler der indeholder disse
MX9706394A (es) Compuestos de 1-aril-2-acilamino-etano y su uso como antagonistas de neuroquinina, especialmente neuroquinina-1.
AU3458997A (en) Anti-beta-amyloid protein-induced cytotoxicity composition
HUP9902465A1 (hu) Új amidínium-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
IE840063L (en) Heterocyclic compound
HU9600996D0 (en) Nitric esters from derivatives of 2-(2,6-dihalophenyl-amino)-phenylacetoxyacetic acid and their preparation procedures
ZA945773B (en) Pharmaceuticals
NZ337142A (en) Hydroxamic acid compounds
EP0839799A4 (en) 2-HYDROXYPHENYLALKYLAMINE DERIVATIVES AND MAILLARD REACTION INHIBITORS
MX9805061A (es) Preparacion estereoselectiva de derivados succinicos 2-substituidos.
TW277059B (es)
HUP9903260A2 (hu) Antibiotikus hatású 2,4-diamino-pirimidin-származékok, előállításuk és alkalmazások

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees